The next wave of cellular immunotherapies in pancreatic cancer

Molecular Therapy: Oncolytics

John E.J. Rasko¹  Payal Saxena²  Caroline Giardina³  Dannel Yeo⁴ 

[1] Cell and Molecular Therapies, Royal Prince Alfred Hospital, Sydney Local Health District, Camperdown, NSW 2050, Australia;Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2050, Australia;Gene Therapy Program, The University of Sydney, Camperdown, NSW 2050, Australia;;Li Ka Shing Cell &

关键词: pancreatic cancer;    cellular immunotherapy;    adoptive T cell therapy;    CAR T cell therapy;    tumor microenvironment;    checkpoint blockade;   

DOI  :  

来源: DOAJ

【 摘 要 】

Pancreatic cancer is an aggressive disease that is predicted to become the second leading cause of cancer-related death worldwide by 2030. The overall 5-year survival rate is around 10%. Pancreatic cancer typically presents late with locally advanced or metastatic disease, and there are limited effective treatments available. Cellular immunotherapy, such as chimeric antigen receptor (CAR) T cell therapy, has had significant success in treating hematological malignancies. However, CAR T cell therapy efficacy in pancreatic cancer has been limited. This review provides an overview of current and ongoing CAR T cell clinical studies of pancreatic cancer and the major challenges and strategies to improve CAR T cell efficacy. These strategies include arming CAR T cells; developing off-the-shelf allogeneic CAR T cells; using other immune CAR cells, like natural killer cells and tumor-infiltrating lymphocytes; and combination therapy. Careful incorporation of preclinical models will enhance management of affected individuals, assisting incorporation of cellular immunotherapies. A multifaceted, personalized approach involving cellular immunotherapy treatment is required to improve pancreatic cancer outcomes.

【 授权许可】

Unknown